SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced a strategic transaction to exclusively ...

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial unveiling of ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of its second generation ...

Expanded Functionality to Support COVID-19 Research Immediately Available Through Early Access “ROSALIND offers powerful data analysis capabilities and a unique ability to facilitate collaboration ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of a Single Cell Gene ...

More than 35 Abstracts Demonstrate the Value of the nCounter Platform for Targeted Discovery, Biomarker Development and Diagnostic Applications in Cancer Research and Immuno-Oncology NanoString’s New ...

45 Abstracts Demonstrate the Value of the nCounter Platform for Immuno-Oncology Research Studies Indicate the Clinical Relevance of the Tumor Inflammation Signature for Multiple Immunotherapies ...

Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently endorse routine ...

HalioDx and NanoString Technologies said today they will partner to develop and commercialize advanced gene expression assays for assessing response to cancer immunotherapies. The value of the ...